The Head of the Department of Preclinical Trials at Celon Pharma was a speaker at the 9th Congress of the “World of the Pharmaceutical Industry”. The subject of his presentation was: Opportunities for the development of innovative therapies in Poland in the light of global R&D trends The Congress of the “World of the PharmaceuticalRead more »
Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking. This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,Read more »
The CEO of Celon Pharma S.A. was a guest of the expert debate held during the Conference: Techonologies of the Future – Biotechnology, which was held on 19 October at the Presidential Palace devoted to the role of biotechnology and perspectives of its development in Poland. We are here today because we believe in biotechnology,Read more »
Ladies and Gentlemen, In connection with the information provided yesterday by Selvita S.A. on withholding the clinical programme for SEL24, the Management Board of Celon Pharma S.A. informs that such situations occur naturally in the process of creating innovative medicinal products, as demonstrated by numerous examples of clinical projects carried out in American or EuropeanRead more »
The event covered a broad scope of issues which are the subject of scientific research in response to challenges faced by the modern pharmaceutical sector. At the congress, Mikołaj Matłoka – Leader of the Neuropsychiatry Research Group at Celon Pharma S.A. – presented issues related to the development of innovative drugs in neuropsychiatric indications.Read more »
President of the Board of Celon Pharma S.A. was a guest of the programme Profit. He answered Agniszka Zaręba’s questions on the company’s results for the first half of 2017, on its presence in international markets and the strategy of global commercialisation of the company’s innovative portfolio. We invite you to view the video.
We encourage you to see the recording and presentation of the Company’s online teleconference held on 25/09/2017 as well as the Q&A session.
A publication dedicated to the company’s financial results in the first half of 2017 and the company’s plans in terms of clinical development of drug candidates. Maciej Wieczorek, PhD: Our generic drugs recorded similar sales rates to last year, which was in line with our expectations. Our financial result in the first half of the year wasRead more »
The Company published its Periodic Report for the 1 half of 2017. The total value of sales generated by the Company in the first half of 2017 amounted to 57 million net, whereas net profit to over 13 million. In terms of volume, the sales of specialised medicinal products which are Polish market leaders inRead more »
20170920_Steady income and positive sales dynamics of Celon Pharma S.A.